04:55 AM EDT, 10/31/2024 (MT Newswires) -- Argenx SE ADR (ARGX) reported Thursday it swung to Q3 net profit of $1.39 per diluted share from $1.25 loss per share a year earlier.

Total operating income for the quarter ended Sept. 30 was $588.9 million, up from $339.8 million a year earlier.

The Dutch immunology company said with an increase in cash, cash equivalents and current financial assets in the quarter and year-to-date, the previously issued cash guidance no longer applies.

The financial guidance on the combined selling, general and administrative expenses and research and development expenses remains unchanged at approximately $2 billion.